Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR2 amp |
Therapy | Dovitinib |
Indication/Tumor Type | Her2-receptor positive breast cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 amp | Her2-receptor positive breast cancer | sensitive | Dovitinib | Phase I | Actionable | In a Phase I trial, Dovitinib (TKI258) displayed safety and preliminary efficacy resulting in tumor regression of 28.2% and 18.5% in two patients with FGFR2 amplified Erbb2 (Her2)-receptor positive breast cancer (PMID: 23658459). | 23658459 |
PubMed Id | Reference Title | Details |
---|---|---|
(23658459) | Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. | Full reference... |